Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications
PathAI, a provider of AI-powered pathology, entered into a partnership with GSK, on HORIZON, a randomized Phase 2b non-alcoholic steatohepatitis (NASH) clinical trial.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced that the organization’s recent research will be presented at the upcoming 2022 AASLD 2022 Liver Meeting*, which will be held in Washington, D.C. from November 4-8, 2022. At this year’s event PathAI will share a total of five presentations, four poster presentations and one oral presentation, four of which were developed in collaboration with pharmaceutical partners. Notably, new findings for nonalcoholic steatohepatitis (NASH) highlight how PathAI continues to address the need for a reproducible and accurate clinical research network (CRN) scoring tool to meet the standards of today’s NASH clinical trials, as well as the need for more robust quantitative measures.
AI pathology specialist PathAI has announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. The initial work within this extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to forward these into clinical trials. PathAI develops quantitative pathology algorithms for drug discovery and development.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. The initial work within this extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to continue transitioning this work into clinical trials.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in AI-powered pathology, today announced that it has appointed Brandon Eldredge as Chief Financial Officer. An experienced financial leader with a track record for delivering value and growth across business segments, Eldredge has helped companies raise more than $5 billion in capital and managed a range of transactions totaling over $15 billion.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in AI-powered pathology, today announced it will present three presentations at this year's International Liver Congress (ILC) in London. The abstracts detail a novel machine learning-enabled continuous scoring system for nonalcoholic steatohepatitis (NASH) that allows for both nuanced analysis of treatment efficacy and capabilities to predict disease progression in patients with advanced fibrosis due to NASH. Further, the research details a novel method to image fibrosis in liver biopsy slides, potentially eliminating the second set of trichrome stain slides that historically have been required.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced that their recent research will be presented at the 2022 AACR annual meeting, which will be held in New Orleans from April 8 to April 13, 2022. PathAI will share a total of six posters, three of which were developed in collaboration with pharmaceutical partners. These new findings have promising implications for improving the diagnosis and treatment of multiple cancer subtypes with the use of AI-powered digital pathology.
BOSTON--(BUSINESS WIRE)--PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“KBI”) for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line. The agreement covers, among other things, both a 200L demonstration run and a 500L cGMP run.